US · BIO
Bio-Rad Laboratories, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Hercules, CA 94547
- Website
- bio-rad.com
Price · as of 2025-12-31
$256.55
Market cap 7.52B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $297.44 | +15.94% |
| Intrinsic Value(DCF) | $129.40 | -49.56% |
| Graham-Dodd Method(GD) | $391.49 | +52.6% |
| Graham Formula(GF) | $242.62 | -5.43% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $103.82 | $143.27 | $16.04 | $77.28 | $97.91 |
| 2012 | $123.55 | $143.89 | $17.64 | $83.63 | $47.49 |
| 2013 | $130.11 | $153.87 | $0.00 | $71.99 | $29.93 |
| 2014 | $134.90 | $132.15 | $5.06 | $73.73 | $30.90 |
| 2015 | $137.36 | $155.05 | $15.43 | $87.72 | $4.82 |
| 2016 | $197.25 | $157.24 | $11.29 | $76.18 | $9.96 |
| 2017 | $274.11 | $215.64 | $4.59 | $101.09 | $47.74 |
| 2018 | $303.86 | $191.14 | $4.73 | $187.88 | $167.81 |
| 2019 | $374.56 | $354.66 | $35.21 | $478.65 | $535.50 |
| 2020 | $559.98 | $624.95 | $41.44 | $962.75 | $2,291.89 |
| 2021 | $529.89 | $647.25 | $14.73 | $1,160.18 | $3,178.39 |
| 2022 | $478.24 | $231.94 | $0.00 | $0.00 | $0.00 |
| 2023 | $343.76 | $220.64 | $2.32 | $176.01 | $0.00 |
| 2024 | $261.19 | $151.48 | $0.00 | $0.00 | $0.00 |
| 2025 | $279.59 | $297.44 | $35.67 | $391.49 | $242.62 |
AI valuation
Our deep-learning model estimates Bio-Rad Laboratories, Inc.'s (BIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $297.44
- Current price
- $256.55
- AI upside
- +15.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$129.40
-49.56% upside
Graham-Dodd
$391.49
+52.6% upside
Graham Formula
$242.62
-5.43% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BIO | Bio-Rad Laboratories, Inc… | $256.55 | 7.52B | +16% | -50% | +53% | -5% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| CRL | Charles River Laboratorie… | $178.49 | 8.78B | -31% | -60% | — | — | -62.27 | 2.80 | 2.20 | 12.85 | — | 146.61 | 30.52% | 12.65% | -3.59% | -4.29% | 8.46% | -1.94% | 0.97 | 4.74 | 1.29 | 0.82 | 3.13 | -155500.00% | -85.00% | 337.00% | 5.86% | 0.66 | 8.64% | 0.00% | 0.00% | 4.07% | 23.05 | 22.57 | 2.91 | 2.48 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| GRFS | Grifols, S.A. | $9.10 | 7.7B | +209% | -64% | — | -49% | 10.85 | 0.82 | 0.67 | 9.37 | 6.98 | -1.08 | 38.75% | 16.53% | 2.18% | 7.89% | 3.72% | 2.09% | 1.71 | 1.54 | 2.66 | 0.96 | 6.13 | 15556.00% | 941.00% | -67929.00% | 11.02% | 0.42 | 3.46% | 0.02% | 0.20% | 28.68% | 11.66 | 26.19 | 1.93 | 0.96 |
| HQY | HealthEquity, Inc. | $76.49 | 6.61B | -8% | -56% | -86% | -60% | 73.84 | 3.38 | 5.95 | 23.56 | 105.02 | -9.68 | 57.73% | 19.18% | 8.06% | 4.66% | 6.98% | 2.92% | 0.52 | 3.79 | 3.06 | 2.65 | 2.41 | 7031.00% | 2003.00% | 7167.00% | 4.73% | 2.17 | 12.30% | 0.00% | 0.00% | 1.70% | 34.57 | 23.55 | 6.63 | 3.98 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| PEN | Penumbra, Inc. | $344.39 | 13.51B | -36% | -28% | -84% | -67% | 74.97 | 9.33 | 9.49 | 59.99 | 6.49 | 10.62 | 67.14% | 13.48% | 12.66% | 13.78% | 13.14% | 10.58% | 0.15 | — | 6.64 | 2.06 | 0.15 | 115556.00% | 1750.00% | 1876.00% | 1.31% | 1.30 | 14.03% | 0.00% | 0.00% | 0.00% | 70.57 | 76.34 | 9.51 | 22.01 |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- CEO
- Norman D. Schwartz
- Employees
- 7.7K
- Beta
- 1.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($129.40 ÷ $256.55) − 1 = -49.56% (DCF, example).